Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
, 238 (2), 329-35

A Randomized Trial of Coenzyme Q10 in Patients With Confirmed Statin Myopathy

Randomized Controlled Trial

A Randomized Trial of Coenzyme Q10 in Patients With Confirmed Statin Myopathy

Beth A Taylor et al. Atherosclerosis.


Background: Coenzyme Q10 (CoQ10) supplementation is the most popular therapy for statin myalgia among both physicians and patients despite limited and conflicting evidence of its efficacy.

Objective: This study examined the effect of coenzyme Q10 (CoQ10) supplementation on simvastatin-associated muscle pain, muscle strength and aerobic performance in patients with confirmed statin myalgia.

Methods: Statin myalgia was confirmed in 120 patients with prior symptoms of statin myalgia using an 8-week randomized, double-blind crossover trial of simvastatin 20 mg/d and placebo. Forty-one subjects developed muscle pain with simvastatin but not with placebo and were randomized to simvastatin 20 mg/d combined with CoQ10 (600 mg/d ubiquinol) or placebo for 8 weeks. Muscle pain (Brief Pain Inventory [BPI]), time to pain onset, arm and leg muscle strength, and maximal oxygen uptake (VO2max) were measured before and after each treatment.

Results: Serum CoQ10 increased from 1.3 ± 0.4 to 5.2 ± 2.3 mcg/mL with simvastatin and CoQ10, but did not increase with simvastatin and placebo (1.3 ± 0.3 to 0.8 ± 0.2) (p < 0.05). BPI pain severity and interference scores increased with simvastatin therapy (both p < 0.01), irrespective of CoQ10 assignment (p = 0.53 and 0.56). There were no changes in muscle strength or VO2max with simvastatin with or without CoQ10 (all p > 0.10). Marginally more subjects reported pain with CoQ10 (14 of 20 vs 7 of 18; p = 0.05). There was no difference in time to pain onset in the CoQ10 (3.0 ± 2.0 weeks) vs. placebo (2.4 ± 2.1 wks) groups (p = 0.55). A similar lack of CoQ10 effect was observed in 24 subjects who were then crossed over to the alternative treatment.

Conclusions: Only 36% of patients complaining of statin myalgia develop symptoms during a randomized, double-blind crossover of statin vs placebo. CoQ10 supplementation does not reduce muscle pain in patients with statin myalgia. Trial RegistrationNCT01140308;

Keywords: Aerobic performance; CoQ10; Exercise; Muscle pain; Muscle strength; Myalgia; Statin; Ubiquinol.

Conflict of interest statement

Conflict of Interest: Mrs. Lorson, and Dr. White do not have any conflict of interest or financial disclosures.


Figure 1
Figure 1
Protocol for Coenzyme Q10 (CoQ10) in Statin Myopathy study. For all study visits, procedures are performed in the order listed. 1Lipids: total cholesterol, low density lipoprotein (LDL)-cholesterol, high density lipoprotein (HDL)-cholesterol, triglycerides. ALT = alanine aminotransferase, CK = creatine kinase, CK-MB = creatine kinase heart-specific isoform, TSH = thyroid-stimulating hormone.
Figure 2
Figure 2
CoQ10 Participant Flow Diagram. Study flow diagram detailing numbers (n) of participants who were screened, randomized, completed and analyzed in the study.

Comment in

Similar articles

See all similar articles

Cited by 31 articles

See all "Cited by" articles

Publication types

MeSH terms

Associated data